Cannabis Compounds Show Promise Against Chemotherapy Nerve Pain, but Clinical Evidence Falls Short

For millions of cancer survivors, the end of chemotherapy is not the end of suffering. Long after the last infusion, many patients live with burning, tingling, and shooting pain in their hands and feet—a condition known as chemotherapy-induced neuropathic pain, or CINP. A new review published in BMC Complementary Medicine and Therapies examines whether the body’s own cannabis-like signaling system, the endocannabinoid system, could hold the key to preventing or treating this debilitating side effect. The verdict from researchers Delia Soriano and María Florencia Coronel of the Laboratorio de Dolor asociado al Cáncer at CONICET–Universidad Austral in Argentina is nuanced: the preclinical science is compelling, but the clinical evidence remains thin, modest, and inconsistent.

CINP is a major dose-limiting toxicity of some of the most widely used chemotherapy classes, including platinum drugs such as oxaliplatin and cisplatin, taxanes like paclitaxel, and vinca alkaloids. Estimates suggest that between 30 and 60 percent of patients receiving certain regimens develop the condition. Clinically, it presents as spontaneous and evoked persistent pain, frequently manifesting as mechanical and thermal allodynia—pain triggered by normally harmless stimuli such as light touch or mild warmth. But the damage does not stop at pain. Patients often experience additional sensory disturbances, motor dysfunction, cognitive impairment, and affective disorders, all of which severely compromise quality of life and, in some cases, force oncologists to reduce or discontinue life-prolonging treatment.

The therapeutic landscape is bleak. According to the review, current preventive measures are essentially lacking, and the treatments that do exist are largely palliative, managing symptoms without addressing the underlying neurobiological mechanisms. Standard analgesics, including some antidepressants and anticonvulsants borrowed from other neuropathic pain conditions, offer incomplete relief for many patients. This gap has driven researchers to look for targets that act on the biology of the damaged nerves themselves—and the endocannabinoid system has emerged as one of the most intriguing candidates.

The endocannabinoid system is the body’s endogenous modulator of pain processing, active under both physiological and pathological conditions. It comprises two principal endogenous ligands, anandamide and 2-arachidonoylglycerol (2-AG), the enzymes that synthesize and metabolize them—including fatty acid amide hydrolase (FAAH), monoacylglycerol lipase (MGL), diacylglycerol lipases (DAGL), and N-acyl phosphatidylethanolamine phospholipase D (NAPE-PLD)—fatty acid-binding proteins and membrane transporters that shuttle the ligands, and two main receptors, cannabinoid receptor type 1 (CB1) and type 2 (CB2). CB1 receptors are densely expressed at central and peripheral sites along the pain pathway, while CB2 receptors are prominent on immune cells and become upregulated in injury states. Together, these components exert multifaceted regulatory effects at the periphery, in the spinal cord, and in the brain.

What makes the endocannabinoid system particularly interesting in the context of CINP is that experimental models show dynamic changes in its components after chemotherapy exposure. Rather than being a static bystander, endogenous cannabinoid signaling appears to become dysregulated as neuropathy develops, suggesting that restoring or enhancing this signaling could be therapeutically useful. Indeed, the review documents that direct or indirect modulation of cannabinoid receptors has been shown to both prevent and mitigate behavioral indicators of pain in CINP models. Strategies include direct agonists such as arachidonyl-2′-chloroethylamide (ACEA), inhibitors of the enzymes that break down anandamide and 2-AG, positive allosteric modulators that fine-tune receptor activity, and interventions targeting the endocannabinoid membrane transporter. Indirect approaches are especially attractive because they amplify endocannabinoid signaling only where and when it is naturally produced, potentially reducing the central side effects—such as psychoactivity—that limit direct CB1 agonism.

Beyond the endocannabinoid system itself, preclinical studies have explored the analgesic and neuroprotective properties of phytocannabinoids derived from the cannabis plant, primarily Δ⁹-tetrahydrocannabinol (THC) and cannabidiol (CBD). The evidence indicates that both compounds, administered alone or in combination, can alleviate neuropathic pain in CINP models. THC acts as a partial agonist at CB1 and CB2 receptors, while CBD has a more complex pharmacology, interacting with transient receptor potential (TRP) channels and other targets, and modulating endocannabinoid tone indirectly. The combination of the two has drawn particular interest because CBD may temper THC’s psychoactive effects while contributing its own analgesic and anti-inflammatory actions. Animal studies of paclitaxel-, oxaliplatin-, and cisplatin-induced neuropathy have reported reductions in mechanical and thermal hypersensitivity following cannabinoid treatment, in some cases with evidence of neuroprotection of sensory neurons in the dorsal root ganglia.

Yet the translation from bench to bedside has been disappointing. The review finds that clinical studies in patients with CINP have reported only modest or inconsistent benefits. Several factors may explain this translational gap. Preclinical models typically use fixed doses and formulations in young, otherwise healthy animals, whereas clinical trials must contend with heterogeneous patient populations, variable chemotherapy regimens, differing stages of neuropathy, and a wide range of cannabinoid products with uncertain composition and bioavailability. Dosing regimens that work in rodents may not map onto tolerable doses in humans, where psychoactive effects of THC and drug interactions with ongoing cancer therapy complicate escalation. The review underscores the need for rigorous preclinical characterization of phytocannabinoid formulations and dosing regimens precisely to bridge this gap—ensuring that the compounds, ratios, doses, and timing tested in animals are those most likely to succeed in the clinic.

The authors also emphasize the broader burden of CINP as a rationale for continued investment. Because the condition can compromise chemotherapy dosing, it affects not only quality of life but potentially oncological outcomes. A therapy that could prevent the onset of neuropathy—or reverse it once established—without interfering with chemotherapy’s anti-tumor efficacy would represent a significant advance. The endocannabinoid system’s position at the interface of neuronal and immune signaling makes it a plausible candidate for such dual protective and analgesic roles, and its modulation offers multiple pharmacological entry points, from enzyme inhibitors to receptor subtype-selective ligands that avoid central psychoactive effects by targeting peripheral CB1 or CB2 receptors.

In synthesizing the field, Soriano and Coronel aim to integrate current knowledge, highlight key translational gaps, and identify priorities for future research. Their critical appraisal makes clear that the story of cannabinoids and chemotherapy-induced neuropathic pain is neither one of simple promise nor of failure. The endocannabinoid system is genuinely dysregulated in experimental CINP, and manipulating it genuinely relieves pain-like behavior in animals. But the leap to effective, safe, and reproducible treatments for patients has not yet been made, and the clinical data that exist are too limited to support confident recommendations. The path forward, the review suggests, lies in better-controlled preclinical studies that mirror clinical conditions, carefully designed formulations and dosing strategies, and clinical trials rigorous enough to determine once and for all whether cannabinoid-based therapies can deliver on the promise that two decades of animal research has generated.

For now, patients and clinicians are left in an uncomfortable middle ground: a biological system with strong mechanistic credentials, a family of compounds with demonstrated preclinical efficacy, and a clinical evidence base that has not kept pace. As cannabis-derived medicines continue to attract public and scientific attention, this review serves as a sober reminder that enthusiasm must be matched by methodological rigor—and that the gap between what works in a mouse and what helps a patient remains one of the most important challenges in cannabinoid pain research.

Subject of Research: The role of the endocannabinoid system and cannabinoid-based therapies in chemotherapy-induced neuropathic pain, from preclinical promise to limited clinical evidence.

Article Title: The endocannabinoid system and cannabinoid-based therapies in chemotherapy-induced neuropathic pain: from preclinical promise to limited clinical evidence

Article References: Soriano, D., & Coronel, M. F. (2026). The endocannabinoid system and cannabinoid-based therapies in chemotherapy-induced neuropathic pain: from preclinical promise to limited clinical evidence. BMC Complementary Medicine and Therapies. https://doi.org/10.1186/s12906-026-05585-y

Image Credits: AI Generated

DOI: 10.1186/s12906-026-05585-y

Keywords: chemotherapy-induced neuropathic pain, endocannabinoid system, cannabinoid receptors, CB1, CB2, THC, cannabidiol, neuropathic pain, phytocannabinoids, allodynia, pain management, cancer survivors